Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
World Journal of Urology
|
February 22, 2016
Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy
A Sivaraman, G Ordaz Jurado, X Cathelineau, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Journal of Endourology
|
May 19, 2010
Focal therapy in prostate cancer-report from a consensus panel
J de la Rosette, H Ahmed, J Barentsz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
B Tombal, A Choudhury, F Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
S Gillessen, E Gallardo, A Choudhury, et al.
Prostate Cancer and Prostatic Diseases
|
May 10, 2017
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
L Tosco, A Laenen, A Briganti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
World Journal of Urology
|
February 22, 2016
Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy
A Sivaraman, G Ordaz Jurado, X Cathelineau, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Journal of Endourology
|
May 19, 2010
Focal therapy in prostate cancer-report from a consensus panel
J de la Rosette, H Ahmed, J Barentsz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
B Tombal, A Choudhury, F Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
S Gillessen, E Gallardo, A Choudhury, et al.
Prostate Cancer and Prostatic Diseases
|
May 10, 2017
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
L Tosco, A Laenen, A Briganti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 6